Electrophysiologic predictors of long-term clinical outcome with amiodarone for refractory ventricular tachycardia secondary to coronary artery disease

Yazaki, Yoshizumi; Haffajee, Charles I.; Gold, R; Bishop, Richard L.; Alpert, Joseph S.

doi:10.1016/0002-9149(87)90230-x

Cited by 26 publications

(1 citation statement)

References 18 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Several studies have suggested that EP-guided therapy can increase the success rate of therapy with amiodarone [40][41][42][43][44][45][46][47]. In these studies lack of inducible ventricular arrhythmias after amiodarone therapy was associated with a better outcome.…”

Section: B: Ep-guided Amiodarone Therapymentioning

confidence: 99%

Can Amiodarone Prevent Sudden Cardiac Death in Patients with Hemodynamically Tolerated Sustained Ventricular Tachycardia and Coronary Artery Disease?

Arya

Haghjoo

Sadr‐Ameli

2005

Cardiovasc Drugs Ther

View full text Add to dashboard Cite

One of the most important challenges in today's cardiology is prevention of sudden cardiac death in high risk patients with coronary artery disease (CAD). Sustained hemodynamically tolerated ventricular tachycardia (HTVT) comprises up to 30% of all cases of monomorphic ventricular tachycardia in patients with CAD. While there is a consensus on treatment of hemodynamically unstable sustained ventricular tachycardia in patients with CAD, some controversies regarding the proper treatment of HTVT exist. We re-examined existing clinical evidence, controversies and current guidelines on the treatment of HTVT in patients with CAD and demonstrated that compared to implantable cardioverter-defibrillator, amiodarone is not an acceptable therapeutic option in patients with ischemic heart disease who suffer from HTVT.

show abstract

Section: B: Ep-guided Amiodarone Therapymentioning

confidence: 99%

Can Amiodarone Prevent Sudden Cardiac Death in Patients with Hemodynamically Tolerated Sustained Ventricular Tachycardia and Coronary Artery Disease?

Arya

Haghjoo

Sadr‐Ameli

2005

Cardiovasc Drugs Ther

View full text Add to dashboard Cite

show abstract

Automatic Implantable Cardioverter Defibrillator

Manolis¹

1989

JAMA

View full text Add to dashboard Cite

The automatic implantable cardioverter defibrillator was conceived by Mirowski as an implantable device for detection and termination of ventricular fibrillation. Since the initial human implant of the defibrillator in 1980, there has been a dramatic expansion of the clinical experience with more than 5000 implants. The technology of the device, which is now capable of sensing and terminating both ventricular tachycardia and fibrillation, has evolved rapidly. Although still not an ideal antiarrhythmic device, it has already had a major impact on arrhythmic mortality with a marked reduction in the sudden death rates in a high-risk patient population.

show abstract

Risk stratification and prognosis of patients treated with amiodarone for malignant ventricular tachyarrhythmias after myocardial infarction

Proclemer

Facchin

Vanuzzo

et al. 1993

Cardiovasc Drug Ther

View full text Add to dashboard Cite

Seventy-seven consecutive patients (mean age 62 years) with episodes of sustained ventricular tachycardia (VT) or ventricular fibrillation (VF) after acute myocardial infarction (AMI) were evaluated to assess the long-term efficacy of first-line amiodarone treatment and to identify clinical and laboratory factors associated with a high risk of death or arrhythmia recurrence. The presenting arrhythmia was VT in 41 cases (53%) and VF in 36 (47%). VT or VF occurred between the 4th and 90th day after AMI in 45 cases (58%) and later (more than 90 days) in the remaining 32 (42%). The mean number of arrhythmic episodes was 4.2. Forty patients (52%) were in New York Heart Association (NYHA) class I or II, and 37 (48%) were in class III or IV. Mean left ventricular ejection fraction was 32%; ventricular aneurysm was present in 41 subjects. Most patients had multivessel coronary artery disease. Amiodarone was administered as a first-choice drug in all patients, in combination with other antiarrhythmic drugs in 14. By ventricular stimulation after loading doses of amiodarone, sustained VT was inducible in 46 (62%) and noninducible in 28 (38%). During a mean follow-up of 28 months the incidence of cardiac mortality at 1, 3, and 5 years was 21%, 37%, and 47%; of sudden death was 7%, 19%, and 23%; of nonfatal VT recurrence was 13%, 13%, and 24%, respectively. The overall incidence of amiodarone side effects was 35%.2+ was a weak predictor only by univariate analysis (p = 0.05).(ABSTRACT TRUNCATED AT 250 WORDS)

show abstract

Electrophysiologic predictors of long-term clinical outcome with amiodarone for refractory ventricular tachycardia secondary to coronary artery disease

Cited by 26 publications

References 18 publications

Can Amiodarone Prevent Sudden Cardiac Death in Patients with Hemodynamically Tolerated Sustained Ventricular Tachycardia and Coronary Artery Disease?

Can Amiodarone Prevent Sudden Cardiac Death in Patients with Hemodynamically Tolerated Sustained Ventricular Tachycardia and Coronary Artery Disease?

Automatic Implantable Cardioverter Defibrillator

Risk stratification and prognosis of patients treated with amiodarone for malignant ventricular tachyarrhythmias after myocardial infarction

Contact Info

Product

Resources

About